Overview of biologic therapy for Crohn's disease

Bibliography

• Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117(3):514-21
   PubMed Web of Science ®Google Scholar
• Sanders DSA. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 2005;58:568-72
   PubMed Web of Science ®Google Scholar
• D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and inflximab and azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 2008;103(S1):S436
   Google Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128(4):862-9
   PubMed Web of Science ®Google Scholar
• Saro C, da la Coba C, Casoda MA, et al. Resource utilization in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther 2007;26(10):1313-23
   PubMed Web of Science ®Google Scholar
• Feagan B, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135(5):1493-9
   PubMed Web of Science ®Google Scholar
• Armstrong AM, Gardiner KR, Kirk SJ, et al. Tumor necrosis factor and inflammatory bowel disease. Br J Surg 1997;84:1051-58
   PubMed Web of Science ®Google Scholar
• Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER. Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol 1989;143(1):127-30
   PubMed Web of Science ®Google Scholar
• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68
   PubMed Web of Science ®Google Scholar
• Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor responses in vivo. J Immunol 2000;165(11):6278-86
   PubMed Web of Science ®Google Scholar
• Danese S, Dejana E, Fiocchi C. Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol 2007;178:6017-22
   PubMed Web of Science ®Google Scholar
• Fiocchi C, Ina K, Danese S, et al. Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases. Adv Exp Med Biol 2007;579:168-76
   Web of Science ®Google Scholar
• Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis 2005;37:811-18
   PubMedGoogle Scholar
• Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 2008;40S:S225-28
   Google Scholar
• Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97:2000-4
   PubMed Web of Science ®Google Scholar
• Danese S, Sans M, Scaldaferri F, et al. TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006;176:2617-24
   PubMed Web of Science ®Google Scholar
• Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14(12):1715-35
   PubMed Web of Science ®Google Scholar
• Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 2007;133(1):312-39
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-9
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6(6):644-53
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN. Inflximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-85
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348(7):601-8
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56(9):1226-31
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44(2):265-7
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Kamm MA, Colombel JF, et al. Sustained steroid-free clinical remission in patients with moderate to severe Crohn's disease treated with adalimumab. Am J Gastroenterol 2006;101(9):S460
   PubMedGoogle Scholar
• Colombel J-F, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940-48
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med 2007;146(12):829-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multileukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353(4):362-8
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol 2008;6(12):1370-7
   PubMed Web of Science ®Google Scholar
• Dall'Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004;13(5):372-6
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double;blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-74
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-41
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for Crohn's disease. N Engl J Med 2004;351(20):2069-79
   PubMed Web of Science ®Google Scholar
• Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55(8):1138-44
   PubMed Web of Science ®Google Scholar
• Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55(8):1131-7
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: subanalysis of CHARM. Gastroenterology 2007;132(4 (Suppl 2)):A147
   Google Scholar
• Sandborn WJ, Colombel JF, Panes J, et al. Higher remission and maintenance of response rates with subcutaneously monthly certolizumab pegol in patients with recent-onset Crohn's disease: Data from PRECiSE 2. Am J Gastroenterol 2006;101(9):S434-5
   Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains long-term remission in Crohn's disease through 2 years. J Crohns Colitis 2008;2(1):5
   Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-center cohort. Gut 2009;58:492-500
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Cohen R, Feagan B, et al. Safety of infliximab and other Crohn's disease therapies: TreatTM Registry data with 24,575 patient-years of follow-up. Am J Gastroenterol 2008;103(S1):S436
   Web of Science ®Google Scholar
• Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis 2007;13(6):769-96
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
   PubMed Web of Science ®Google Scholar
• Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124-9
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictor's of Crohn's disease. Gastroenterology 2006;130(3):650-6
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lin YC, Dutridge D. Serum immune responses predict rapid progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360-7
   PubMed Web of Science ®Google Scholar
• Riis L, Vind I, Vermeire S. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007;13:24-32
   PubMed Web of Science ®Google Scholar
• Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modeling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28(1):76-87
   PubMed Web of Science ®Google Scholar